Phase 1b trial evaluates HC-7366 with venetoclax and azacitidine in relapsed/refractory AML, suggesting potential benefits against resistance mechanisms.
Key Points
Monotherapy with HC-7366 may improve outcomes for patients with acute myeloid leukemia and TP53 mutations.
A phase 1b trial is assessing potential benefits of HC-7366 combined with venetoclax and azacitidine.
Current therapies show limited efficacy; activation of the integrated stress response may target resistant leukemic stem cells.
HC-7366's role in overcoming MCL-1 mediated resistance highlights its promise in future treatments for relapsed AML.